

SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

THE LYMPHOMAS CONFERENCE

III EDITION

ROME
08/09
MAY
2026



A. ROMA LIFESTYLE HOTEL, ROME
Via Giorgio Zoega, 59

PRESIDENTS:

Gerardo Musuraca, Nicola Normanno

SCIENTIFIC SECRETARIAT:


Claudio Cerchione, Eliana Liardo,
Alessandro Lucchesi, Francesco Malaspina,
Giovanni Martinelli, Margherita Parolini,
Costantino Riemma, Jessica Rosa, Pietro Rossi

PROMOTED BY

Unità Ematologia e Trapianti IRCCS IRST "Dino Amadori" Meldola

ORGANIZING SECRETARIAT





08.05.2026

DAY 1

8:30 REGISTRATION

WELCOME AND INTRODUCTION

→ SESSION 1:

The biology of the Diffuse Large B cell Lymphoma

Chairs: Gerardo Musuraca and Giovanni Martinelli

09:00 – 09:20

- *Louis Staudt*

The pathways of Diffuse large B-cell lymphomas (DLBCL):
Classifications and artificial intelligence to understand the “enemy”

09:20 – 09:40

- *Riccardo dalla Favera*

What we know about the genetics of diffuse large cell lymphoma
and how it makes it work

09:40 – 10:00

- *Laura Pasqualucci*

Microenvironment and interaction with genetics in controlling
DLBCL development and resistance

10:00 – 10:10

- *L. Staudt, L. Pasqualucci, R. Dalla Favera, G. Martinelli, G. Musuraca*

“Rumble in the jungle”
Which are the best drivers? Suggestions for future therapies

→ SESSION 2:

Diffuse Large B cell Lymphoma: Treatment strategies - PART A

Chairs: Umberto Vitolo, Greg Nowakoski, Claudio Cerchione

10:10 - 10:30

• *Grzegorz Nowakowski*

Biology driven or agnostic: The Multiverse in the first line of DLBCL

10:30 - 10:50

• *Stephen Schuster*

Relapsed/refractory: The CAR T way and the current landscape of cellular therapies

10:50 - 11:20

• *Gerardo Musuraca*

Relapsed/refractory: Looking for the best sequencing or salvage strategy (Bispecifics, Drug conjugates and friends)

11:20 - 11:40

• *Lapo Alinari*

Relapsed/refractory LBCL: The evolution of the CAR T cells: Allo, NK, bi or trispecific

11:40 - 11:50 COFFEE BREAK

→ **SESSION 2:**

Diffuse Large B cell Lymphoma: Treatment strategies - PART B

Chairs: Stefan Hohaus, Patrizia Tosi, Mark Roschewsky

11:50-12:10

- *Grzegorz Nowakowski*
High Grade Lymphomas

12:10-12:30

- *Umberto Vitolo*
Next strategies and molecules on the window

12:30-12:50

- *Mark Roschewsky*
ctDNA in Large B cell Lymphoma

12:50-13:10

- *Francesco Malaspina*
Artificial intelligence in the DLBCL "Instructions for use " to build future treatments of DLBCL

**13:10 - 14:10 LUNCH SYMPOSIUM
ROOM: GIOVE 2**

Sponsored Symposium NO ECM - with the contribution of ABBVIE

Chair: Gerardo Musuraca

13:10-13:30

- *Francesco Piazza*
Learning from italian experience: from the speed of action to the management of patients with epcoritamab in R/R NHL

13:30-13:35

Discussion

→ **SESSION 3:**

Hodgkin Lymphoma

Chairs: Antonello Pinto, Anna Sureda

14:10-14:30

• *Ralf Koppers*

The biology of Hodgkin Lymphoma

14:30-14:50

• *Antonello Pinto*

First-line treatment in Hodgkin lymphoma: The evolving landscape

14:50-15:20

• *Anna Sureda*

Relapsed/refractory HL: Salvage treatments strategies: All you need to know about transplant and new drugs

15:20-15:30

• *A. Sureda, A. Pinto, R. Koppers*

"Rumble in the jungle"

The wind of change in Hodgkin Lymphoma

15:30 - 15:50 COFFEE BREAK

→ **SESSION 4:**

Mantle cell lymphoma

Chairs: Enrico Derenzini, Kami Maddocks

15:50-16:20

• *Kami Maddocks*

Lecture: From the biology to target cure. A risk based approach in the Front line strategies

16:20-16:40

• *Elisabeth Silkenstedt*

Salvage treatments in relapsed or refractory patients: Now and beyond.

16:40-17:00

• *Lapo Alinari*

CAR T cells in MCL: Current landscape and future prospectives.

17:00-17:10

• *K. Maddocks, E.Silkenstedt, L. Alinari, E. Derenzini*

"Rumble in the jungle"

What we have ahead in mantle cell lymphoma

→ **SESSION 5:**

Marginal Zone Lymphoma and Waldenstrom Macroglobulinemia

Chairs: Emanuele Zucca , Davide Rossi

17:10-17:30

• *Davide Rossi*

Marginal zone Lymphoma: A particular journey from the biology to the clinic in first line.

17:30-17:50

• *Emanuele Zucca*

Marginal zone lymphoma: From the failure of the front line to the next future

17:50-18:20

• *Steven Treon*

Waldenstrom Macroglobulinemia: From diagnosis to therapy: What we have learned and what lies ahead

Chair: Francesco Lanza

18:20-18:50

• *Antonio Pierini*

Lecture: Allotransplant in Lymphoma: Who, when and How ? Update in 2025 in the era of cell therapies and new drug

18:50 CLOSING DAY REMARKS



09.05.2026

DAY 2

→ SESSION 6:

Follicular lymphoma

Chairs: Alessandro Pulsoni, Alessandro Lucchesi

- *Laura Pasqualucci*

Genetic and Epigenetic of transformation in Follicular lymphoma

08:50-09:10

- *Stefano Luminari*

First line therapy: State of the art and state of the future

09:10-09:30

- *Pietro Rossi*

Relapse/refractory disease before and beyond CAR T

09:30-09:50

- *Stephen Schuster*

CAR T cell: Is there a role in follicular lymphoma instead of other compounds?

09:50- 10:10

10:10 – 11:05 COFFEE BREAK SYMPOSIA
ROOM: GIOVE 2

Chairs: Gerardo Musuraca

Sponsored Symposium NO ECM - with the contribution of ABBVIE

Sailing through the Bcl-2 inhibition pathway

10:10-10:30

- *Gianluca Gaidano*

V+X: venetoclax as the backbone therapy in 1L and R/R CLL

10:30-10:35

Discussion

Sponsored Symposium NO ECM - with the contribution of LILLY

Translating Novel BTK Inhibition into Clinical Decisions

10:35-10:50

- *Antonio Cuneo*

Treatment Guidelines and Clinical Efficacy of Pirtobrutinib: Evidence from the BRUIN-CLL-321

10:50-11:00

- *Antonio Cuneo*

Clinical Practice: A Case-Based Discussion in Relapsed/Refractory CLL

11:00-11:05

Discussion

→ SESSION 7:

Chronic Lymphocytic Leukemia

Chairs: Luca Laurenti

11:05-11:25

• *Gianluca Gaidano*

The biology that leads to treatment: Why the drugs work in CLL

11:25-11:45

• *Lydia Scarfo'*

The right treatment in the right patient: Which first-line and why ?

11:45-12:05

• *Talha Munir*

What we have to use and when, if we fail in CLL

→ **SESSION 8:**

Special types of lymphomas

Chairs: Maurizio Martelli, Christina Cox

• *Enrico Derenzini*

T-cell lymphomas: From the biology to the treatments

12:05-12:25

• *Andres Ferreri*

Primary CNS Lymphoma: Everything you need to know

12:25-12:50

• *Maurizio Martelli*

Primary Mediastinal Diffuse large B cell lymphoma: Do we know what the best strategy is to treat it?

12:50-13:10

• *Mark Roschewsky*

Burkitt Lymphoma: To know and tame the monster

13:10-13:30

• *Alessandro Pileri*

Primary cutaneous lymphomas

13:30-13:50

13:50 CLOSING REMARKS
GERARDO MUSURACA, NICOLA NORMANNO

13:50 LUNCH BOX

SEE YOU NEXT YEAR!

GOLD

abbvie

Lilly A MEDICINE COMPANY

SILVER

AstraZeneca 

 BeOne

Johnson & Johnson



BRONZE

 GILEAD

 Kite



SOLVE
ON.

 KYOWA KIRIN

 sobi

